Company to present data on new designer cell lines metabolically engineered to
overcome the specific expression bottlenecks associated with difficult-to-express proteins.
Geneva, Switzerland (PRWEB) January 06, 2012
Selexis SA announced today data from the Company’s SUREtechnology Platform™ will be presented at the 11th Annual PepTalk Conference, January 9-13, 2011 at the Hotel Del Coronado in San Diego, California.
Selexis’ chief scientific officer, Pierre-Alain Girod, Ph.D., will present, “Engineering CHO Cell Line For Enhanced Production of MAbs and Fc:Fusion Proteins,” on Tuesday, January 10 at 12:15 as part of the biotherapeutic’s ‘targeting protein-protein interactions’ tract.
The Chinese hamster ovary (CHO) cell line is the predominant host for the production of therapeutic proteins. However, the CHO cell remains poorly efficient in high production levels for certain classes difficult to express proteins, such as fusion proteins. We have identified proteins of the cell’s secretion pathway system which are able to enhance the yield of difficult to express proteins. Co-expression of these proteins improved cell line’s expression from titers of the protein below 0.3 gr/L up to 2 gr/L in a fed-batch process. We have thus developed new designer cell lines metabolically engineered to overcome the specific expression bottlenecks associated with difficult-to-express proteins.
Dr. Girod and the company’s chief technology officer, Dr. Armelle Gaussin, will be available for questions at Selexis booth 40 from January 9 – 13. Please see conference website for complete schedule.
About Selexis SA
Headquartered in Geneva, Switzerland, Selexis SA is a global life science company with innovative technologies and world-class expert services for drug discovery, cell line development and scale-up to manufacturing of therapeutic proteins. The Company's SUREtechnology Platform™ is based on Selexis Genetic Elements™ -- novel DNA-based elements that control the dynamic organization of chromatin within all mammalian cells and allow for higher and more stable expression of recombinant proteins. Selexis has generated over 1,300 cell lines being used in a variety of programs from drug discovery to late-stage clinical trials. The Company anticipates three products manufactured from cell lines using the Selexis SUREtechnology Platform™ to be launched in 2012.
more information, visit http://www.selexis.com